You searched for "prostate cancer"

143 results found

Prostate cancer

Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...

Cryotherapy in prostate cancer

This review of the literature aims to summarise what is known in regards to outcomes in patients undergoing cryotherapy in a number of settings: whole gland, salvage and targeted focal therapy. It highlights that more prostate cancers are being diagnosed...

Focal therapies in prostate cancer

The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Biomarkers in prostate cancer detection

Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

Rotterdam Prostate Cancer Risk app

The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...

Impact of MetS on prostate cancer (PCa)

Metabolic syndrome is associated with an increased risk of finding prostate cancer (PCa) overall and high-grade disease on biopsy. The first objective was to determine if MetS is associated with higher final PCa stage and grade on radical prostatectomy (RP)...

Improving on the Rotterdam Prostate Cancer Risk Calculator

Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...

COVID-19 cuts prostate cancer referrals in half

Charity warns that 3500 men risk being diagnosed with incurable cancer as referrals drop to lowest in 10 years Urgent referrals for urological cancers have dropped by half in England (49.5%) compared to the same period last year as the...

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer

Despite prostate cancer being one of the most commonly diagnosed cancers worldwide, there remains a need for high-quality evidence regarding the optimal treatment choice. In this large population-based cohort study, using the PCBaSe Sweden dataset, Sooriakumaran and colleagues identified patients...

Metabolic syndrome and prostate cancer recurrence in a veterans’ cohort

This study explored the relationship between metabolic syndrome and localised prostate cancer recurrence in patients who had received active treatment (external beam radiation therapy – EBRT, radical retropubic prostatectomy – RRP, or brachytherapy). The definition of metabolic syndrome adopted was...

Focal therapy for prostate cancer – ready for prime time?

The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

The role of transperineal template biopsies in the diagnosis of prostate cancer

The case In 2002, Mr A, a 64-year-old software engineer, was referred by his GP for further investigation of a raised prostate specific antigen (PSA) of 6.2. His prostate felt benign. He underwent transrectal ultrasound guided (TRUS) prostate biopsies. This...